XERS Q4 2018 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$982M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$801,000+71.5% YoY

Gross Profit

$759,00094.8% margin

Operating Income

-$20M-2536.1% margin

Net Income

-$20M-2549.2% margin

EPS (Diluted)

$-0.98

QoQ Revenue Growth

+37.6%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$19M

Stock-Based Comp.

$579,000

Balance Sheet

Total Assets

$120M

Total Liabilities

$45M

Stockholders' Equity

$75M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$801,000	$467,000	+71.5%
Gross Profit	$759,000	$467,000	+62.5%
Operating Income	-$20M	-$9M	-120.6%
Net Income	-$20M	-$9M	-123.3%